GLP-1, Fasting Insulin & HOMA-IR: Insulin Resistance

Fasting insulin and HOMA-IR (a calculation from fasting glucose × fasting insulin) are the everyday markers of insulin resistance — the core metabolic problem behind type 2 diabetes, PCOS, fatty liver, and much obesity-related disease. On a GLP-1 they generally improve: in the STEP 1 trial, semaglutide reduced fasting serum insulin and HOMA-IR versus placebo (Kosiborod 2023 ^[1]), and other randomized data show the same direction (Anyiam 2024 ^[2]; Arslanian 2026 ^[3]). The improvement is driven mostly by weight loss, with help from the drug's glucose-dependent action on the pancreas. A falling fasting insulin / HOMA-IR is one of the most encouraging things to watch — it means your body is becoming more sensitive to its own insulin. Here's what the numbers mean and their limits.

The honest summary

• Fasting insulin and HOMA-IR usually fall. In STEP 1, semaglutide significantly reduced fasting serum insulin and HOMA-IR versus placebo (Kosiborod 2023^[1]) — a sign of improving insulin sensitivity.
• It tracks with weight loss. Insulin resistance is tightly linked to body fat (especially visceral and liver fat); GLP-1 weight loss is the main driver of the improvement.
• The drug also acts on the pancreas — glucose-dependently. GLP-1 enhances insulin secretion only when glucose is elevated, which is why it improves glycemic control without causing low blood sugar on its own.
• Consistent across populations. Improvements in insulin sensitivity show up in adults (Anyiam 2024^[2]) and adolescents (STEP TEENS, Arslanian 2026^[3]).
• HOMA-IR is a useful trend marker, not a precise gauge. It's an estimate; single values bounce around, and it isn't validated for people already on insulin. Watch the direction over time, with your clinician.

What fasting insulin and HOMA-IR actually measure

When you're insulin resistant, your tissues respond poorly to insulin, so the pancreas pumps out more of it to keep glucose in range. That shows up as a high fasting insulin even when fasting glucose still looks normal — which is why fasting insulin can flag a problem years before blood sugar does. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting glucose and fasting insulin into a single number estimating that resistance. As insulin sensitivity improves, the pancreas can do the same job with less insulin, so fasting insulin and HOMA-IR both come down. That downward move is the metabolic signal you want.

What the trials show

Kosiborod 2023^[1] examined cardiometabolic risk factors in STEP 1 and STEP 4 (once-weekly semaglutide 2.4 mg in overweight/obesity without diabetes). In STEP 1, reductions in fasting serum insulin and HOMA-IR — alongside waist circumference, blood pressure, fasting glucose, and lipids — were significantly greater with semaglutide than placebo. Anyiam 2024^[2] (Clinical Nutrition) compared the metabolic effects of a very-low-calorie diet, semaglutide, or both in type 2 diabetes and likewise documented improved insulin/metabolic measures. And in adolescents, the STEP TEENS analysis (Arslanian 2026^[3], Diabetes Care) reported improved insulin sensitivity and cardiometabolic risk factors with semaglutide. The throughline: as weight and fat fall, the body needs less insulin to manage glucose.

The limits of these markers

HOMA-IR is an estimate, not a gold-standard measurement (that would be a research-grade clamp study). Practical caveats: a single fasting insulin can vary with stress, recent meals, and lab assay, so one reading means little — the trend is what matters. HOMA-IR is not valid in people already taking insulin (exogenous insulin distorts the calculation), and it's less reliable in advanced beta-cell failure. Fasting insulin also isn't a routine screening test everywhere, and reference ranges vary by lab. Use these as a direction-of-travel marker your clinician interprets in context — not a number to fixate on or self-diagnose from.

What to do with your numbers

• Fasting insulin / HOMA-IR trending down: favorable — your insulin sensitivity is improving as you lose weight. Track the trend at follow-up.
• Single high or odd value: don't over-read it — repeat in context; these markers are noisy.
• On insulin therapy: HOMA-IR isn't valid for you; your clinician will judge insulin sensitivity differently (and may be reducing your insulin dose as the GLP-1 helps).
• PCOS or fatty liver: improving insulin resistance is central to both — a falling HOMA-IR is a meaningful marker of progress beyond weight alone.

Bottom line

GLP-1 therapy lowers fasting insulin and improves HOMA-IR^[1][2][3], reflecting better insulin sensitivity — the metabolic root issue behind type 2 diabetes, PCOS, and fatty liver. It's driven mostly by weight loss, with the drug's glucose-dependent pancreatic effect on top. Treat these as encouraging trend markers, not precise gauges (and not valid if you're on insulin), and interpret the direction over time with your clinician.